Print Page  Close Window

SEC Filings

S-1
VITAE PHARMACEUTICALS, INC filed this Form S-1 on 08/12/2014
Entire Document
 

Table of Contents


 
  As of December 31    
 
 
  As of
June 30,
2014
 
 
  2013   2012  
 
   
   
  (unaudited)
 
 
  (in thousands)
 

Balance sheet data:

                   

Cash, cash equivalents, and marketable securities

  $ 32,454   $ 24,782   $ 18,141  

Working capital

    23,905     27,173     10,031  

Total assets

    34,028     35,329     20,562  

Notes payable, including current portion

    10,086     14,506     7,505  

Convertible preferred stock

    125,870     125,870     125,870  

Accumulated deficit

    (110,877 )   (112,016 )   (120,896 )

Total stockholders' deficit

    (106,894 )   (108,224 )   (116,763 )

(1)
See Note 2 to our financial statements for an explanation of the method used to calculate net income (loss) per share of common stock, basic and diluted, pro forma net income (loss) per share of common stock, basic and diluted, and the basic and diluted pro forma weighted average shares outstanding used to calculate the pro forma per share amounts.

53